The Conference will return in November 2021, Register Your Interest Here

7:55 am
Chair’s Opening Remarks

  • Shannon Turley Vice President, Immunology & OMNI Biomarker Discovery, Genentech

Tackling Fibrosis: Where Are We With Antifibrotic Drug Development?

8:00 am Discussion Panel: Debating the Commonalities & Disparities Between the Different Fibrotic Disease Indications & Organ Specific Fibroses

Bridging the Translational Gap: Clinical & Preclinical Biomarkers

8:30 am Discussing Myofibroblast Membrane Receptors as Targets for PET-Imaging Tracers in Fibrosis & Fibrotic Cancer Stroma

  • Herman Steen Co-Founder & Chief Executive Officer, BiOrion Technologies

Synopsis

  • Highlighting the translatability of fibrogenesis biomarkers across disease states
  • Divulging the relevance of upregulated myofibroblast membrane receptors as sensitive fibrogenesis biomarkers to be used in PET-imaging of fibrogenesis in organ fibrosis and fibrotic cancer
  • Proving early therapeutic effectiveness to give confidence taking the drug development forward

9:00 am Extracellular Matrix Remodeling is the Common Denominator in All Chronic Diseases

Synopsis

  • Using collagens to quantify the balance between formation and degradation of tissues
  • Highlighting the importance of targeting the right epitope of the right protein
  • Illuminating that biomarkers of the extracellular matrix are key in understanding pathological pathways

9:30 am Integrating Multi-Omics Approaches to Identify Relevant Biomarkers for Fibrosis Clinical Trials

Synopsis

  • Discussing the translatability of combining biomarkers across disease states and indications
  • Detecting peripheral biomarkers using transcriptomics and proteomics
  • Considering how this applies across indications and how to harness this knowledge
  • Illuminating novel biomarkers to capture the translatability bridge into humans

10:00 am
Speed Networking

Synopsis

  • This session is the perfect opportunity to get face-to-face time with the key opinion leaders in the fibrosis field
  • Establish meaningful business relationships to build upon for the rest of the conference and gain individual insight into the pioneering work ongoing

10:45 am
Morning Break

Basic Science & Early Translational

Examining Novel In Vitro & In Vivo Modelling to Drive a New Era of Fibrotic Drug Development

  • Ken Dower Associate Research Fellow, Head of Fibrosis Discovery Biology, Pfizer

11:00 am Understanding Fibroblast Heterogeneity in Target Organs Across Inflammatory & Fibrotic Diseases

  • Kevin Wei Assistant Professor, Harvard University

Synopsis

  • Revealing fibroblast heterogeneity in human diseases using single-cell profiling
  • Uncovering niche signals which govern fibroblast fates in diseases using spatial profiling

11:30 am Session Reserved for Physiogenix

11:45 am Discovery of Novel Anti-Fibrotic Targets in an In Vitro Human Surrogate System of Nonalcoholic Steatohepatitis (NASH)

  • Ryan Feaver Executive Director & Head of Exploratory Biology, HemoShear

Synopsis

  • Highlighting a novel in vitro cell culture system to explore phenotypic changes in stellate cells
  • Evaluating fibrotic biomarkers suitable for in vitro applications
  • Using RNAseq and bioinformatics for identifying and validating new therapeutic targets for reversing liver fibrosis

12:15 pm Harnessing Organ on a Chip Models to Improve Representation of the Human Condition

Synopsis

  • Illuminating the importance of biologically relevant tissue culture environment for in vitro studies
  • Exploring the effect of mechanical stretch and flow on cellular function
  • Highlighting rapid ex vivo assessment of therapeutic efficacy in human cells under more realistic physiologic conditions
  • Discussing relevant experimental readouts

Later Translational & In-Human

Illuminating the Latest in Fibrotic Biomarkers Across Indications to Harness Predictive & Progressive Biomarkers In Clinical Development

  • Shannon Turley Vice President, Immunology & OMNI Biomarker Discovery, Genentech

11:00 am Crossing the divide: Leveraging Fibrosis- Inflammatory Biomarkers to Inform Clinical Trial Design

  • Adi Mor Chief Scientific Officer, Chemomab

Synopsis

  • Highlighting the predictive and progressive biomarkers used in later translational and in-human studies
  • Debating which biomarkers to harness in clinical trial design

11:30 am Session Reserved for Antaros Medical

12:00 pm Treating Scleroderma by Targeting Pro-Fibrotic Macrophages: Highlighting Biomarkers of M2-like Macrophages-Levels in Systemic Sclerosis

  • Richard Stratton Professor of Exeprimental Medicine, Centre for Rheumatology and Connective Tissue Diseases | UCL Divison of Medicine

Synopsis

  • Highlighting macrophage activation states and the role of M2-like macrophages in fibrosis
  • Exploring novel approaches to targeting this type of pathogenic cell

12:25 pm
Roundtable Discussion Groups:
Deliberating Bench to Bedside Biomarkers

Synopsis

This session facilitates in-depth discussion amongst participants. A topic will be given to the table to discuss, make a case for and against and then to feedback to the chair. This session is intended to be thought-provoking and a chance to speak to peers across disciplines.

  • Non-Invasive vs Invasive Biomarkers to predict and detect fibrosis across fibrotic indications
  • Harnessing knowledge and practices cross-organ, cross disease, and cross-discipline

12:45 pm
Lunch

Basic Science & Early Translational

Navigating Repairing & Regenerating Tissue to Address Fibrosis

  • Ken Dower Associate Research Fellow, Head of Fibrosis Discovery Biology, Pfizer

1:45 pm Delving Into Transcriptional Programming & Immune Interactions That Influence Fibroblast Regenerative Competence

Synopsis

  • Understanding key transcriptional programs underlying regenerative versus fibroblast fates during skin wound healing
  • Highlighting inflammatory immune signalling restrains fibroblast regenerative potential
  • Illuminating new insights from a unique large animal model of skin regeneration

2:30 pm Turning Back the Clock Across Organs: Regenerating Fibrotic Loss & Preventing Progression Towards Organ Failure

Synopsis

  • Decoding secreted proteins for new therapeutics targets in regenerating fibrotic loss
  • Upregulating repair pathways
  • Illuminating the possibilities of regenerative medicine for antifibrotics across organ function

Later Translational & In-Human

Illuminating the Latest in Fibrotic Biomarkers Across Indications to Harness Predictive & Progressive Biomarkers In Clinical Development

  • Shannon Turley Vice President, Immunology & OMNI Biomarker Discovery, Genentech

1:45 pm
Panel Discussion:
Validating Biomarkers Across Trials & Diseases: Illuminating Learnings from the Lung, Kidney & Liver

  • Eric White Senior Clinical Program Lead, Boehringer Ingelheim
  • Shannon Turley Vice President, Immunology & OMNI Biomarker Discovery, Genentech

Synopsis

  • This is your chance to ask your burning questions to the expert panel
  • Discussing everything surrounding validating biomarkers for clinical trials and across diseases to illuminate learnings we can harness cross-disease and cross-organ

2:30 pm Discussing Biomarkers of Progressive Kidney Function Decline as Biomarkers of Kidney Fibrosis

Synopsis

  • Illuminating biomarkers to identify patients at risk
  • Predicting effectiveness of reno-protective drugs with biomarkers
  • Monitoring effectiveness of reno-protective drugs using biomarkers

3:00 pm
Afternoon Break – Poster Session

Synopsis

Connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships, whilst exploring the latest antifibrotic drug development advances

To submit a poster or to find out more, contact info@hansonwade.com

The Fibrosis Umbrella: Understandings & Developments to Accelerate Effective Fibrotic Therapeutics

4:00 pm Discussing SIX1 Driven Mechanisms in Lung & Skin Fibrosis: A Potential for Gene Therapy?

Synopsis

  • Introducing the SIX1 pathway in diseases
  • Understanding of how SIX1 alters epithelial cell function in lung fibrosis
  • Appreciating how SIX1 expression in adipocytes contributes to skin fibrosis

4:30 pm Dynamic Fibrogenesis in Human Precision Cut Tissue Slices: An Unrivalled Preclinical Platform for Development & Testing of Anti- Fibrotic Therapies

Synopsis

  • Explore how human liver, kidney, heart and lung precision cut tissue slices (PCTS) retain the cellular complexity and architecture of the native tissue in culture
  • Discover established, dynamic models of tissue inflammation, fibrogenesis, and cancer
  • Discuss the application of PCTS for drug testing, target engagement, and assessment of tissue viability and metabolic activity

5:00 pm Understanding the Role of the 5-HT2B Receptor in Fibrosis with Special Focus on Systemic Sclerosis-ILD

Synopsis

  • Exploring the mechanism of action
  • Using a variety of preclinical models to evaluate the therapeutic’s effectiveness
  • Harnessing RNA sequencing to show target engagement in relevant cells
  • Moving from Phase 1 into systemic sclerosis patients with focus on biomarkers

5:30 pm Chair’s Closing Remarks & End of Day One